Skip to main content

DISPOSITIVOS AVANZADOS DE LIBERACION CONTROLADA DE AGENTES GENICOS TERAPEUTICOS BASADOS EN BIOMATERIALES NANOESTRUCTURADOS BIOMIMETICOS

MAT2016-79435-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE VALLADOLID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

An elastin-like recombinamer-based bioactive hydrogel embedded with mesenchymal stromal cells as an injectable scaffold for osteochondral repair

  • Cipriani, Filippo
  • Ariño Palao, Blanca
  • González de Torre, Israel
  • Vega Castrillo, Aurelio
  • Aguado Hernández, Héctor José
  • Alonso Rodrigo, Matilde
  • Álvarez Barcia, Ángel José
  • Sánchez, Ana
  • García Diaz, Verónica
  • López Peña, Mónica
  • Rodríguez Cabello, José Carlos
The aim of this study was to evaluate injectable, in situ cross-linkable elastin-like recombinamers (ELRs) for osteochondral repair. Both the ELR-based hydrogel alone and the ELR-based hydrogel embedded with rabbit mesenchymal stromal cells (rMSCs) were tested for the regeneration of critical subchondral defects in 10 New Zealand rabbits. Thus, cylindrical osteochondral defects were filled with an aqueous solution of ELRs and the animals sacrificed at 4 months for histological and gross evaluation of features of biomaterial performance, including integration, cellular infiltration, surrounding matrix quality and the new matrix in the defects. Although both approaches helped cartilage regeneration, the results suggest that the specific composition of the rMSC-containing hydrogel permitted adequate bone regeneration, whereas the ELR-based hydrogel alone led to an excellent regeneration of hyaline cartilage. In conclusion, the ELR cross-linker solution can be easily delivered and forms a stable well-integrated hydrogel that supports infiltration and de novo matrix synthesis
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Elastin-like recombinamer-based devices releasing Kv1.3 blockers for the prevention of intimal hyperplasia: An in vitro and in vivo study

  • Moreno-Estar, Sara
  • Serrano, Sofía
  • Arévalo-Martínez, Marycarmen
  • Cidad, Pilar
  • López-López, José R.
  • Santos, Mercedes
  • Pérez-García, M. Teresa
  • Arias, Francisco Javier
Coronary artery disease (CAD) is the most common cardiovascular disorder. Vascular surgery strategies for coronary revascularization (either percutaneous or open) show a high rate of failure because of restenosis of the vessel, due to phenotypic switch of vascular smooth muscle cells (VSMCs) leading to proliferation and migration. We have previously reported that the inhibition of Kv1.3 channel function with selective blockers represents an effective strategy for the prevention of restenosis in human vessels used for coronary angioplasty procedures. However, delivery systems for controlled release of these drugs have not been investigated. Here we tested the efficacy of several formulations of elastin like recombinamers (ELRs) hydrogels to deliver the Kv1.3 blocker PAP-1 in various restenosis models. The dose and time course of PAP-1 release from ELRs click hydrogels was able to inhibit human VSMC proliferation in vitro as well as remodeling of human vessels in organ culture and restenosis in in vivo models. We conclude that this combination of active compound and advanced delivery method could improve the outcomes of vascular surgery in patients., The authors are grateful for financial support from the European Social Fund (ESF) and the European Regional Development Fund (ERDF), as well as grants from the EU H2020-NMP-2014-646075), the Spanish Ministerio de Economia y Competitividad MINECO (grants BFU2016-75360-R, DTS19/00162, MAT2016-79435-R, MAT2016-78903-R and RTI2018-096320-B-C22), the Junta de Castilla y León (grants VA114P17 and VA317P18), the CIBER-BBN, the JCyL and the Instituto de Salud Carlos III under the “Network Center of Regenerative Medicine and Cellular Therapy of Castilla and Leon”. S. Moreno-Estar and S. Serrano are predoctoral fellows of the Junta de Castilla y León and M. Arévalo-Martínez is predoctoral fellow of UVa-Santander.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus

  • Gonzalez-Valdivieso, Juan
  • Borrego, Belén
  • Girotti, Alessandra
  • Moreno, Sandra
  • Brun Torres, Alejandro
  • Bermejo-Martin, Jesús
  • Arias, F. Javier
13 Pág., This work analyzes the immunogenicity of six genetically engineered constructs based on elastin-like recombinamers (ELRs) fused to the Gn glycoprotein from Rift Valley fever virus (RVFV). Upon transfection, all constructs showed no effect on cell viability. While fusion constructs including ELR blocks containing hydrophobic amino acids (alanine or isoleucine) did not increase the expression of viral Gn in eukaryotic cells, glutamic acid- or valine-rich fusion proteins showed enhanced expression levels compared with the constructs encoding the viral antigen alone. However, in vivo DNA plasmid immunization assays determined that the more hydrophobic constructs reduced viremia levels after RVFV challenge to a higher extent than glutamic- or valine-rich encoding plasmids and were better inducers of cellular immunity as judged by in vitro restimulation experiments. Although the Gn-ELR fusion constructs did not surpass the protective efficacy of a plasmid vaccine expressing nonfused Gn, our results warrant further experiments directed to take advantage of the immunomodulatory potential of ELR biomaterials for improving vaccines against infectious diseases., The authors are grateful for financial support from the European Social Fund (ESF) and the European Regional Development Fund (ERDF), as well as funding from the EU (H2020-NMP-2014-646075), the MICIUN (DTS19/00162, MAT2016-79435-R, MAT2016-78903-R and AGL2017-82336-R), the Comunidad de Madrid (project S2018/BAA-4370) the JCyL (project VA317P18), the CIBER-BBN, the JCyL and the Instituto de Salud Carlos III under the “Network Center of Regenerative Medicine and Cellular Therapy of Castilla and Leon”., Peer reviewed